Director of Reproductive Medicine Center at Qinzhou Maternity and Child Healthcare Hospital , China
👩⚕️ Dr. Wu Hongbo is the Director of the Reproductive Medicine Center at Qinzhou Maternity and Child Healthcare Hospital. She holds a doctorate from Xiangya School of Medicine, Central South University. As a chief physician, she specializes in reproductive health, addressing complex fertility issues like recurrent miscarriage, diminished ovarian reserve, and IVF challenges. With numerous SCI publications and leadership in provincial research projects, Dr. Wu has pioneered advancements in reproductive technology. She actively contributes to Guangxi’s reproductive health committees and associations, driving innovative healthcare solutions in assisted reproduction.
Publication Profile
orcid
scopus
Education 🎓
Dr. Wu Hongbo earned her doctorate from Xiangya School of Medicine, Central South University, a prestigious institution renowned for excellence in medical sciences. Her advanced education in reproductive medicine equipped her with specialized knowledge and clinical expertise. Dr. Wu’s academic journey reflects a dedication to mastering cutting-edge fertility treatments and reproductive technology, forming the foundation for her groundbreaking work in assisted reproduction.
Experience 🩺
Dr. Wu Hongbo serves as the Chief Physician and Director of the Reproductive Medicine Center at Qinzhou Maternity and Child Healthcare Hospital. With years of hands-on experience, she leads innovative treatments in reproductive health. Her extensive career includes managing complex IVF cases, recurrent pregnancy loss, and pioneering stem cell applications in endometrial treatments. Dr. Wu also engages in collaborative telemedicine and nursing practices for IVF patients, shaping comprehensive fertility care models.
Awards and Honors 🏆
Dr. Wu Hongbo has been recognized for her excellence in reproductive medicine with leadership roles in the Guangxi Eugenics Association and Guangxi Medical Association. Her work has earned her prestigious appointments, including Vice President of the Healthy Reproduction and Assisted Reproductive Technology Branch and executive committee roles across key reproductive health organizations.
Research Focus 🔬
Dr. Wu Hongbo focuses on reproductive health innovations, including stem cell therapy, ovarian reserve, and assisted reproductive technologies. Her current projects explore menstrual blood-derived mesenchymal stem cells, warm acupuncture therapies, and genetic factors influencing recurrent miscarriage. Through cutting-edge research, she advances fertility treatments, addressing complex reproductive challenges to improve patient outcomes.
Publications 📖
NAT10-mediated mRNA N4-acetylcytidine modifications in mouse oocytes constitute a checkpoint of ovarian follicle development
Journal: Science Bulletin (2024)
DOI: 10.1016/j.scib.2024.09.020
Summary: This study uncovers the role of NAT10-mediated mRNA modifications in ovarian follicle development, providing insights into molecular mechanisms governing oocyte quality and fertility.
2. PCBP1/2 and TDP43 Function as NAT10 Adaptors to Mediate mRNA ac4C Formation in Mammalian Cells
Journal: Advanced Science (2024)
DOI: 10.1002/advs.202400133
Summary: This research identifies PCBP1/2 and TDP43 as critical adaptors in mRNA acetylation, shedding light on gene regulation pathways essential for cell function and development.
3. SARS-CoV-2 infection negatively impacts the quality of embryos by delaying early embryonic development
Journal: American Journal of Reproductive Immunology (2024)
DOI: 10.1111/aji.13831
Summary: The study highlights how COVID-19 affects embryonic development, with implications for fertility treatments and maternal health during the pandemic.
4. Administration of depot GnRH agonist prior to programmed frozen-thawed embryo transfer does not improve live birth rates in ovulatory women
Journal: Medicine (United States) (2022)
DOI: 10.1097/MD.0000000000030991
Summary: This large-scale retrospective study evaluates the effectiveness of GnRH agonists in embryo transfer, influencing clinical protocols for IVF.
5. The function of metformin in endometrial receptivity (ER) of patients with PCOS: A systematic review and meta-analysis
Journal: Reproductive Biology and Endocrinology (2021)
DOI: 10.1186/s12958-021-00772-7
Summary: This meta-analysis explores the beneficial effects of metformin on endometrial receptivity in PCOS patients, supporting its use in fertility treatments.
Conclusion
The candidate demonstrates exceptional expertise and contributions to reproductive medicine, both in research and clinical practice. Their work on genetic research, clinical outcomes in IVF, and their leadership in various reproductive medicine associations make them a strong contender for the Best Researcher Award. Their future research could benefit from broader international engagement and interdisciplinary approaches to continue driving innovation in the field.